Ogilvy CEO John Seifert on Martin Sorrell's exit: 'The show must go on'

Ogilvy CEO John Seifert on Martin Sorrell's exit: 'The show must go on'

Seifert said feedback from clients has been positive.

PBMs, drugmakers face off over copay accumulators

PBMs, drugmakers face off over copay accumulators

As with most drug pricing battles, patients yet again are caught in the crossfire.

Five things for pharma marketers to know: Wednesday, April 18, 2018

Five things for pharma marketers to know: Wednesday, April 18, 2018

Sanders introduces opioid bill; GW gets nod from FDA for Epidiolex; Sanofi sells generic unit to Advent for $2.4 billion.

The MM&M buyer's guide to boutique consulting services

The MM&M buyer's guide to boutique consulting services

You've seen what the biggies can do. What about the smaller end of the spectrum? MM&M's second buyer's guide to pharma, healthcare, and life sciences consulting services focuses on the dos and don'ts of hiring boutique firms.

Omnicom Health's CEO on agency consolidation and why Japan's healthcare market is a 'bellwether'

Omnicom Health's CEO on agency consolidation and why Japan's healthcare market is a 'bellwether'

The healthcare marketing group made another major acquisition in the country last month.

Omnicom beats estimates in Q1, but sees slight dip in North America

Omnicom beats estimates in Q1, but sees slight dip in North America

Omnicom's healthcare revenue was up 2.7% in Q1

Five things for pharma marketers to know: Tuesday, April 18, 2018

Five things for pharma marketers to know: Tuesday, April 18, 2018

J&J Q1 numbers beat expectations; Amazon scraps pharma product distribution plan; FDA works to develop regulatory processes for AI.

Sorrell on Sorrell: ex-WPP chief in his own words

Sorrell on Sorrell: ex-WPP chief in his own words

Campaign looks back at some of Sir Martin Sorrell's musings, barbs and pearls of wisdom in recent times.

Spectrum brings on biopharma, biotech, creative execs

Spectrum brings on biopharma, biotech, creative execs

The firm hired five senior staff in the past month.

Five things for pharma marketers to know: Monday, April 16, 2018

Five things for pharma marketers to know: Monday, April 16, 2018

Shire sale of oncology business makes it more affordable for Takeda; FDA reverses course on Alkermes depression drug; Sorrell out as WPP CEO.

Forensic, focused, cantankerous: nine reflections on Sorrell and his style

Forensic, focused, cantankerous: nine reflections on Sorrell and his style

As Sir Martin clears his desk, PRWeek has collected nine thoughts from the worlds of PR, journalism and agency life on the man, his skills, his temperament, and his future.

Sorrell exit could spell the end for WPP, analysts say

Sorrell exit could spell the end for WPP, analysts say

Martin Sorrell's resignation as chief executive of WPP could lead to a breakup of the company and spark other major changes.

Sorrell departs WPP: how an outsider shaped the global ad industry

Sorrell departs WPP: how an outsider shaped the global ad industry

John Tylee examines how a man who never ran an agency rose to become such a dominant force.

Sorrell quits as WPP chief executive

Sorrell quits as WPP chief executive

Martin Sorrell has stood down as chief executive of WPP, the company has announced.

WPP board to meet as Sorrell probe nears conclusion

WPP board to meet as Sorrell probe nears conclusion

WPP's board of directors is set to meet as it awaits the outcome of an investigation into the personal conduct of CEO Martin Sorrell.

Five things for pharma marketers to know: Friday, April 13, 2018

Five things for pharma marketers to know: Friday, April 13, 2018

FDA investigates unapproved herpes vaccine; DC launches PReP campaign; J&J ordered to pay $80 million in damages in asbestos suit.

Marian Salzman exits Havas PR for Philip Morris International

Marian Salzman exits Havas PR for Philip Morris International

She is relocating to Switzerland for the role.

Crisis communicators give Zuckerberg high marks for testimony

Crisis communicators give Zuckerberg high marks for testimony

The Facebook CEO did not wilt during this week's marathon Senate session.

Agency M&As up 126% globally, with U.S. leading the way

Agency M&As up 126% globally, with U.S. leading the way

U.S. deals through the end of March increased 366% compared with last year.

Pfizer signs 20-year lease for new New York City headquarters

Pfizer signs 20-year lease for new New York City headquarters

The pharma giant will take up 15 floors of a new Manhattan skyscraper.

Former GSW creative chief Dave Sonderman joins The Shipyard

Former GSW creative chief Dave Sonderman joins The Shipyard

Sonderman had worked at GSW since 2001.

Survey: Half of women don't focus on their own health

Survey: Half of women don't focus on their own health

GCI Health, HealthyWomen, and Redbook magazine are using survey insights to inform the HealthiHer movement.

Five things for pharma marketers to know: Wednesday, April 11, 2018

Five things for pharma marketers to know: Wednesday, April 11, 2018

Alexion buys Wilson in latest pharma deal; Drug performance software company Aetion gets financial backing; Roche stops enrollment in combo study after patient deaths.

Facebook share price rebounds after Zuckerberg's testimony

Facebook share price rebounds after Zuckerberg's testimony

Despite the US Congress's lack of insight into Facebook's operations, Mark Zuckerberg's handling of the situation seems to have restored investor confidence in the company.

Read the April 2018 Digital Edition

Read the April 2018 Digital Edition

Read the April 2018 issue in its entirety.

What's the state of diversity in healthcare agencies?

What's the state of diversity in healthcare agencies?

The 2018 MM&M/Publicis Health Diversity Survey is open.

Five things for pharma marketers to know: Tuesday, April 10, 2018

Five things for pharma marketers to know: Tuesday, April 10, 2018

White House to allow states to determine health benefits required by Obamacare; FDA orders Essure sales restrictions; Researchers recommend redefining Alzheimer's.

APCO hires Nancy Turett as healthcare executive director

APCO hires Nancy Turett as healthcare executive director

Turett spent 25 years at Edelman before launching her own firm in 2013.

Angela Gillespie named president of W2O WCG

Angela Gillespie named president of W2O WCG

Gillespie will report to W2O president Jennifer Gottlieb.

Arthur Sadoun: 'Nobody is talking about the client of the future'

Arthur Sadoun: 'Nobody is talking about the client of the future'

The industry is being disrupted and marketers are part of the equation.

Sorrell probe findings could land next week

Sorrell probe findings could land next week

WPP's investigation into alleged misconduct by founder and chief executive Sir Martin Sorrell could be concluded by next week, according to reports.

Five things for pharma marketers to know: Monday, April 9, 2018

Five things for pharma marketers to know: Monday, April 9, 2018

Novartis to buy AveXis; Merck lung cancer drug meets primary goal in trial; "Pharma bro" duo expose more drug pricing flaws.

When TV doctors call you to make an appointment

When TV doctors call you to make an appointment

Actor Patrick Dempsey is helping patients get over the pressure of scheduling an appointment

Five things for pharma marketers to know: Friday, April 6, 2018

Five things for pharma marketers to know: Friday, April 6, 2018

Facebook puts hospital patient data project on hold; Pharma companies' spending on advocacy under the microscope; Naloxone made more widely available.

Johnson & Johnson marketing executive Debra Bass joins Nuvo

Johnson & Johnson marketing executive Debra Bass joins Nuvo

She will lead Nuvo Group's U.S. operations and head marketing globally.

Five things for pharma marketers to know: Thursday, April 5, 2018

Five things for pharma marketers to know: Thursday, April 5, 2018

Gottlieb asks for internet providers' help fighting opioid crisis; Ferring acquires Rebiotix; AbbVie reaches deal with Biogen to delay Humira rival.

High-profile candidates challenge marketers well in advance of launch

High-profile candidates challenge marketers well in advance of launch

With pharma facing ongoing scrutiny of its pricing practices, medical marketers are increasingly asked to demonstrate the superior value of new therapies. High-profile candidates in immunology, pain management, and melanoma challenge marketers well in advance of launch.

Five things for pharma marketers to know: Wednesday, April 4, 2018

Five things for pharma marketers to know: Wednesday, April 4, 2018

Obamacare signup total misses 2017 numbers; Feds warn of "nightmare bacteria"; Lilly, startup reach $473 million deal on diabetes work.

Pro ad report 2017: Ad revenue plunged for print-first publishers

Pro ad report 2017: Ad revenue plunged for print-first publishers

The 2017 numbers aren't kind to print-first publishers. Is this a blip in print's fortunes or the start of a long-predicted decline?

Dr. Reddy's Laboratories CEO of developed markets Alok Sonig makes Wall Street listen

Dr. Reddy's Laboratories CEO of developed markets Alok Sonig makes Wall Street listen

Alok Sonig, chief executive officer of developed markets at Dr. Reddy's Laboratories, articulates the benefits of generics.

Read the March 2018 Digital Edition

Read the March 2018 Digital Edition

Read the March 2018 issue in its entirety.

AbbVie veteran Mark Stenhouse joins Cologuard as president

AbbVie veteran Mark Stenhouse joins Cologuard as president

He spent more than 30 years at the pharmaceutical company.

Five things for pharma marketers to know: Tuesday, April 3, 2018

Five things for pharma marketers to know: Tuesday, April 3, 2018

Celgene COO exits; Study: Most Americans think ACA marketplaces are "collapsing"; Average payments to insurers to increase by more than expected in 2019.

DTC ads 2017: The good, the bad, and the ugly

DTC ads 2017: The good, the bad, and the ugly

We considered pharma and healthcare ads that, per iSpotTV, started airing no earlier than January 2017.

DTC Report 2018: Will more supersized campaigns follow Opdivo's and Keytruda's massive strikes?

DTC Report 2018: Will more supersized campaigns follow Opdivo's and Keytruda's massive strikes?

Following massive strikes by Opdivo and Keytruda, will more supersized campaigns follow?

Five things for pharma marketers to know: Monday, April 2, 2018

Five things for pharma marketers to know: Monday, April 2, 2018

FDA won't review Alkermes' depression drug; Nature Methods retracts paper on CRISPR; Eli Lilly's new R&D chief plans aggressive strategy.

Infographic | AI's impact on patients and caregivers

Infographic | AI's impact on patients and caregivers

Caregivers and patients predict how the use of AI will affect them.

Five things for pharma marketers to know: Friday, March 30, 2018

Five things for pharma marketers to know: Friday, March 30, 2018

Walmart and Humana have started acquisition talks; Blue Cross and Blue Shield says opioids should not be the first treatment option to manage pain

Five things for pharma marketers to know: Thursday, March 29, 2018

Five things for pharma marketers to know: Thursday, March 29, 2018

PhRMA has released a series of new ads that blame high drug prices on cost increases to insurers and PBMs; Veterans Affairs Secretary Dr. David Shulkin has been fired; UK biotech Redx has suspended a Phase I/II trial of its cancer drug

CDM New York's Chris Palmer on 5 a.m. wake-ups, Reddit, and what he's reading

CDM New York's Chris Palmer on 5 a.m. wake-ups, Reddit, and what he's reading

Chris Palmer, president of CDM New York, shares his wake-up routine, what he's reading and his dream of owning a record store if he wasn't in the medical marketing field.

Five things for pharma marketers to know: Wednesday, March 28, 2018

Five things for pharma marketers to know: Wednesday, March 28, 2018

Takeda considers Shire acquisition; Rite Aid transfers nearly 2,000 stores to Walgreens; Oscar raises $165 million in latest funding round.

Omnicom Health to acquire Elsevier's Japan pharma comms business

Omnicom Health to acquire Elsevier's Japan pharma comms business

The business unit will be rebranded as EMC K.K.

Brite Media acquires point-of-care company Mesmerize Marketing

Brite Media acquires point-of-care company Mesmerize Marketing

Mesmerize provides static ad materials at the point-of-care, including physician offices and pharmacies.

Five things for pharma marketers to know: Tuesday, March 27, 2018

Five things for pharma marketers to know: Tuesday, March 27, 2018

GSK to buy out Novartis' stake in consumer healthcare partnership; Aetna to pass on prescription drug rebates to members; California drug price transparency law shows results.

Five things for pharma marketers to know: Monday, March 26, 2018

Five things for pharma marketers to know: Monday, March 26, 2018

Ablynx drops vobarilizumab; Investors unimpressed by Biohaven migraine drug meeting benchmarks; Trump administration prison anti-opioid push relies on naltrexone.

WPP, Omnicom restructure agency set-ups for Johnson & Johnson

WPP, Omnicom restructure agency set-ups for Johnson & Johnson

Omnicom's Velocity and WPP's Neighborhood are new networks supporting J&J.

ICER said a $14,000 drug should be a fraction of the cost. Why its makers listened.

ICER said a $14,000 drug should be a fraction of the cost. Why its makers listened.

In an unusual twist, the makers of cholesterol drug Praluent are re-pricing the treatment to align with the nonprofit's recommendation. Is industry warming to ICER?

ePharma: Novo Nordisk's lessons from a diabetes education campaign

ePharma: Novo Nordisk's lessons from a diabetes education campaign

Why the drugmaker's partnership with a YouTube star is still getting hits.

Five things for pharma marketers to know: Friday, March 23, 2018

Five things for pharma marketers to know: Friday, March 23, 2018

GSK yanks bid for Pfizer consumer health business; Latest government spending bill includes more for FDA; Chantix fails teen study.

Ogilvy CommonHealth names Andrew Schirmer CEO

Ogilvy CommonHealth names Andrew Schirmer CEO

Schirmer previously led McCann Global Health as president for nearly five years.

Five things for pharma marketers to know: Thursday, March 22, 2018

Five things for pharma marketers to know: Thursday, March 22, 2018

Anti-opioid-abuse funding in federal budget bill, healthcare market stabilization out; Redfield tapped to lead CDC; Healthcare companies look to pharma for leadership.

Cannes Lions names new chairman

Cannes Lions names new chairman

Philip Thomas takes over from Terry Savage.

Rbb Communications forms Healthcare Advisory Council

Rbb Communications forms Healthcare Advisory Council

The council, made up of seasoned pharma execs, will function as consultants to rbb's health clients and health team.

McCaskill takes aim at DTC ad tax deduction; measure expected to face stiff resistance

McCaskill takes aim at DTC ad tax deduction; measure expected to face stiff resistance

Pharma companies are likely to put up aggressive resistance to the measure, introduced earlier this month.

Five things for pharma marketers to know: Wednesday, March 21, 2018

Five things for pharma marketers to know: Wednesday, March 21, 2018

J&J CFO plans September retirement; GSK pharma chief to turn business towards oncology, immunology; MM&M unveils 2018 list of healthcare transformers, innovation catalysts.

AI's marketing problem: Inflated claims, outsized expectations may actually be slowing AI's move into clinical practice

AI's marketing problem: Inflated claims, outsized expectations may actually be slowing AI's move into clinical practice

The potential is real, but companies and technology gurus often speak of machine learning as a catch-all solution. The hype may be slowing AI's incremental growth in healthcare, experts say.

MM&M announces its 2018 Healthcare Transformer and Innovation Catalyst honorees

MM&M announces its 2018 Healthcare Transformer and Innovation Catalyst honorees

MM&M has announced its annual showcase of executives, investors, entrepreneurs, designers and thinkers who are ushering the industry into its new technological golden era.

Michael Roth: business change requires financial incentives and holding people accountable

Michael Roth: business change requires financial incentives and holding people accountable

Interpublic Group chairman and chief executive told Advertising Week Europe how he managed to turn an "all white, all male" company into one with 54% female leadership.

Five things for pharma marketers to know: Tuesday, March 20, 2018

Five things for pharma marketers to know: Tuesday, March 20, 2018

Roche's immunotherapy Tecentriq, when combined with a Abraxane-based chemo, decreased the risk of disease worsening or death compared to chemo alone in first-line patients with advanced squamous non-small cell lung cancer; President Trump spoke about using federal prosecutors to sue opioid makers; Trump also vowed to bring down the cost of prescription drugs.

Five things for pharma marketers to know: Monday, March 19, 2018

Five things for pharma marketers to know: Monday, March 19, 2018

Congress has spent less than a quarter of the $500 million to fight the opioid epidemic; The #MeToo movement is gaining steam in the medical industry; Dr. Robert R. Redfield, a leading AIDS researcher, is the top candidate to lead the Centers for Disease Control and Prevention.

No slowing down: Orphan drug designations skyrocket in 2017

No slowing down: Orphan drug designations skyrocket in 2017

The pace may even pick up again this year.

FDA to study HCP views of pharma promotions this year

FDA to study HCP views of pharma promotions this year

The research will also cover topics including disease awareness ads.

Five things for pharma marketers to know: Friday, March 16, 2018

Five things for pharma marketers to know: Friday, March 16, 2018

Pfizer persuades Read to stay another year; House GOP to take another crack at "right to try"; Lundbeck plans to acquire Prexton Therapeutics.

The infectious disease doctor mining the microbiome for drugs

The infectious disease doctor mining the microbiome for drugs

How Seres CEO Roger Pomerantz went from an infectious disease doctor to mining the microbiome for drugs.

Five things for pharma marketers to know: Thursday, March 15, 2018

Five things for pharma marketers to know: Thursday, March 15, 2018

FDA moves to limit nicotine in cigarettes; Alexion reports positive test for rare blood disorder treatment; Oregon governor signs drug pricing transparency bill.

What is a digital medicine, exactly? Akili co-founder Adam Gazzaley explains

What is a digital medicine, exactly? Akili co-founder Adam Gazzaley explains

MM&M spoke with Gazzaley about what's next for Akili, how he defines "digital medicine," and where the field is currently positioned on the hype cycle.

Five things for pharma marketers to know: Wednesday, March 14, 2018

Five things for pharma marketers to know: Wednesday, March 14, 2018

Why the U.S. spends more on healthcare with worse results; Alnylam goes it alone on rare disease therapy; MorphoSys hopes for accelerated approval on MOR208.

Forum: Should outcomes-based pricing be the blueprint for all specialty drug launches?

Forum: Should outcomes-based pricing be the blueprint for all specialty drug launches?

As drugmakers continue to experiment with novel pricing models for expensive new specialty drugs, MM&M asked a trio of industry insiders whether outcomes-based pricing should become standard.

Rise of the health-tech ethicist

Rise of the health-tech ethicist

Want to get an ethicist agitated? Mention the integration of voice-activation and other tech into healthcare. Experts say navigating this area is a work in progress.

Five things for pharma marketers to know: Tuesday, March 13, 2018

Five things for pharma marketers to know: Tuesday, March 13, 2018

UnitedHealth names Witty as Optum CEO; Gilead R&D chief to exit; Novartis ups chief digital officer to executive committee.

DTC pharma ad spending slipped 4.6% in 2017: Kantar

DTC pharma ad spending slipped 4.6% in 2017: Kantar

Direct-to-consumer drug marketing spend dropped most heavily in the magazine and digital categories.

SXSW: Tech empathy, data skepticism, and a Black Eyed Pea fuel health track's surge

SXSW: Tech empathy, data skepticism, and a Black Eyed Pea fuel health track's surge

Health's popularity at SXSW continues to build. Here's our opening weekend wrap-up.

Five things for pharma marketers to know: Monday, March 12, 2018

Five things for pharma marketers to know: Monday, March 12, 2018

Regeneron, Sanofi cut cost of Praluent for wider coverage; GSK to maintain Advair exclusivity for 2018; 'Right to try' bill introduced in House.

Five things for pharma marketers to know: Friday, March 9, 2018

Five things for pharma marketers to know: Friday, March 9, 2018

White House quashes Idaho's insurance plans; Voyager reports positive results in clinical trial for Parkinson's drug; Cigna-Express Scripts deal to face long review.

Infographic | What Makes Patients Tick?

Infographic | What Makes Patients Tick?

Now more than ever, patients aren't shy about sharing their wants and needs. Here, 8,000 patients from three generations in the U.S., U.K., Germany, and France weigh in on everything from brand loyalty to the factors that drive their decision-making-processes to the reasons they switch treatments.

Briana Ferrigno promoted to president of McCann Global Health

Briana Ferrigno promoted to president of McCann Global Health

She was one of the firm's original staffers in 2013.

FCB Health launches creative branding agency

FCB Health launches creative branding agency

The NY-based shop is known as BX: Brand Experience Design Group.

Five things for pharma marketers to know: Thursday, March 8, 2018

Five things for pharma marketers to know: Thursday, March 8, 2018

Cigna to buy Express Scripts for $52B; Gottlieb says 'rigged' system is keeping drug prices high; Sanofi, Evotec speed up infectious disease research.

Has DTC in the oncology space kept up with science?

Has DTC in the oncology space kept up with science?

As oncology drugs save or extend the lives of many more patients than anyone could have imagined a few years ago, a new challenge has emerged in the wake of their approval: Selling them to patients scared about their prognosis and alternately ignorant of and skeptical about recent breakthroughs in treatment.

Five things for pharma marketers to know: Wednesday, March 7, 2018

Five things for pharma marketers to know: Wednesday, March 7, 2018

FDA approves 23andMe breast cancer test, with a warning; Novartis partners with Science 37 on clinical trials using mobile devices; European regulator calls for suspension of Zinbryta.

Ortho CEO leads massive turnaround

Ortho CEO leads massive turnaround

When Ortho Clinical Diagnostics lived under the roof of Johnson & Johnson, it had the luxury of focusing on its product and service mix — and not a whole lot else.

Guidemark Health appoints Michael Parisi as CEO

Guidemark Health appoints Michael Parisi as CEO

He was previously a managing partner at Ogilvy CommonHealth.

Xbox for Docs: Pharma backs AR games for use in physician learning

Xbox for Docs: Pharma backs AR games for use in physician learning

Pharma has backed a number of AR-based games for physician learning and marketing. They're meant to complement live learning, but mobile games may do a better job teaching certain skills.

Walgreens hires Gulden Mesara to lead U.S. communications

Walgreens hires Gulden Mesara to lead U.S. communications

Mesara previously worked in communications for pharma companies AbbVie, Abbott, and Pfizer.

Five things for pharma marketers to know: Tuesday, March 6, 2018

Five things for pharma marketers to know: Tuesday, March 6, 2018

UnitedHealth to pass on rebates to customers; Arkansas adds Medicaid work requirements; American College of Physicians reveals Type 2 diabetes guidelines.

JPA Health Communications hires three senior execs

JPA Health Communications hires three senior execs

The firm recently brought on SVPs in its Washington and Boston offices.

Five things for pharma marketers to know: Monday, March 5, 2018

Five things for pharma marketers to know: Monday, March 5, 2018

Dermira likely to shelve experimental acne drug; Biotech companies apply to use Crispr gene-editing tool; Another setback for Santhera's Raxone.

Marketers Trend Report 2018: Relief after one year of Trump doesn't mitigate all concerns

Marketers Trend Report 2018: Relief after one year of Trump doesn't mitigate all concerns

The general sense: Nobody should get comfortable with the status quo

Teva rebrands in North America amid global restructuring

Teva rebrands in North America amid global restructuring

The pharmaceutical company is undergoing a global restructuring as it relaunches its brand in the U.S. and Canada.

MM&M launches Agency A-to-Z survey

MM&M launches Agency A-to-Z survey

The results will appear in MM&M's Agency A-to-Z directory, which will appear in the magazine's July issue.